Sciencast Management’s VistaGen Therapeutics VTGN Stock Holding History

Sciencast Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-333	Closed	-$21K	–	720
2021 Q1	$21K	Buy	+333	New	+$22.2K	﹤0.01%	472

Other funds holding VTGN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sciencast Management's VTGN Position: Q2 2021 in Review

Sciencast Management sold out of VistaGen Therapeutics (VTGN) in Q2 2021, closing a stake of 333 shares — an estimated $21K sold.

Sciencast Management first reported a position in VTGN in Q1 2021 and held it in 1 quarter. The position peaked at $21K in Q1 2021. 101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

Sciencast Management reported no remaining VistaGen Therapeutics position as of Q2 2021 after selling out during the quarter.
Sciencast Management sold 333 VistaGen Therapeutics shares in Q2 2021, an estimated $21K.
Sciencast Management first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 1 quarter.
Sciencast Management's VistaGen Therapeutics position peaked at $21K in Q1 2021.
101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on Sciencast Management's 13F filing for Q2 2021, filed 28 Jul 2021.